Proteome profiling of formalin‑fixed, paraffin‑embedded lung adenocarcinoma tissues using a tandem mass tag‑based quantitative proteomics approach

Xie,Qi; Wang,Dan; Luo,Xiao; Li,Zhen; Hu,Aixia; Yang,Hui; Tang,Jinxing; Gao,Peiyu; Sun,Tingyi; Kong,Lingfei

doi:10.3892/ol.2021.12967

Proteome profiling of formalin‑fixed, paraffin‑embedded lung adenocarcinoma tissues using a tandem mass tag‑based quantitative proteomics approach

Authors:
- Qi Xie
- Dan Wang
- Xiao Luo
- Zhen Li
- Aixia Hu
- Hui Yang
- Jinxing Tang
- Peiyu Gao
- Tingyi Sun
- Lingfei Kong
View Affiliations

Affiliations: Department of Pathology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan 450003, P.R China, Department of Neorology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan 450003, P.R China, International Medical Center, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan 450003, P.R China, Department of Thoracic Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan 450003, P.R China
Published online on: August 4, 2021 https://doi.org/10.3892/ol.2021.12967
Article Number: 706
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Over the past few decades, increasing efforts have been made to improve the understanding of, and treatment options for, lung adenocarcinoma (LUAD). However, considering the heterogeneity of LUAD, precise proteomics‑based characterization at the molecular level is an urgent clinical requirement for effective treatment. Formalin‑fixed, paraffin‑embedded (FFPE) tissue is a good option as the working tool for proteomics studies. The present study aimed to obtain a global protein profile using LUAD FFPE tissue samples. Using a quantitative proteomics approach, the study revealed that 360 proteins were significantly more highly expressed in LUAD than in adjacent nontumor lung tissues. Also, 19 differentially expressed membrane proteins were found to be primarily responsible for immune processes. Epidermal growth factor (EGF)‑like domain and laminin EGF domain showed markedly different expression levels between cancer tissues and tumor‑adjacent normal tissues. Furthermore, Gene Ontology functional enrichment analysis showed that significantly upregulated proteins were associated with the endoplasmic reticulum lumen, protein disulfide isomerase activity, vitamin binding, cell cycle G1/S phase transition, to name but a few. Also, numerous kinases and post‑translational modification enzymes were significantly upregulated across all eight LUAD samples compared with paracarcinoma tissues. Proteomics analysis revealed that AAA domain containing 3A (ATAD3a), a member of the ATPase family, was highly expressed in LUAD tissues, which was supported by immunohistochemical analysis. Furthermore, the study confirmed that ATAD3a enhanced the cisplatin sensitivity of LUAD cells. Collectively, the findings of the present study provide new potential candidate targets in patients with LUAD, and may aid auxiliary LUAD diagnosis and surveillance in a noninvasive manner.

View Figures

View References

1	Bezzecchi E, Ronzio M, Semeghini V, Andrioletti V, Mantovani R and Dolfini D: NF-YA overexpression in lung cancer: LUAD. Genes (Basel). 11:1982020. View Article : Google Scholar : PubMed/NCBI
2	Xu M, Wang D, Wang X and Zhang Y: Correlation between mucin biology and tumor heterogeneity in lung cancer. Semin Cell Dev Biol. 64:73–78. 2017. View Article : Google Scholar : PubMed/NCBI
3	Haragan A, Field JK, Davies MPA, Escriu C, Gruver A and Gosney JR: Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. Lung Cancer. 134:79–84. 2019. View Article : Google Scholar : PubMed/NCBI
4	Böttge F, Schaaij-Visser TB, de Reus I, Piersma SR, Pham T, Nagel R, Brakenhoff RH, Thunnissen E, Smit EF and Jimenez CR: Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. J Proteomics. 196:106–119. 2019. View Article : Google Scholar : PubMed/NCBI
5	Wang Y, Tian M, Chang Y, Xue C and Li Z: Investigation of structural proteins in sea cucumber (Apostichopus japonicus) body wall. Sci Rep. 10:187442020. View Article : Google Scholar : PubMed/NCBI
6	Bradshaw RA, Hondermarck H and Rodriguez H: Cancer proteomics and the elusive diagnostic biomarkers. Proteomics. 19:e18004452019. View Article : Google Scholar : PubMed/NCBI
7	Wang C, Yang S, Jin L, Dai G, Yao Q, Xiang H, Zhang Y, Liu X and Xue B: Biological and clinical significance of GATA3 detected from TCGA database and FFPE sample in bladder cancer patients. Onco Targets Ther. 13:945–958. 2020. View Article : Google Scholar : PubMed/NCBI
8	Zhong J, Ye Z, Clark CR, Lenz SW, Nguyen JH, Yan H, Robertson KD, Farrugia G, Zhang Z, Ordog T and Lee JH: Enhanced and controlled chromatin extraction from FFPE tissues and the application to ChIP-seq. BMC Genomics. 20:2492019. View Article : Google Scholar : PubMed/NCBI
9	Greytak SR, Engel KB, Bass BP and Moore HM: Accuracy of molecular data generated with FFPE biospecimens: Lessons from the Literature. Cancer Res. 75:1541–157. 2015. View Article : Google Scholar : PubMed/NCBI
10	Zakrzewski F, Gieldon L, Rump A, Seifert M, Grützmann K, Krüger A, Loos S, Zeugner S, Hackmann K, Porrmann J, et al: Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples. BMC Cancer. 19:3962019. View Article : Google Scholar : PubMed/NCBI
11	Coscia F, Doll S, Bech JM, Schweize L, Mund A, Lengyel E, Lindebjerg J, Madsen GI, Moreira JM and Mann M: A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis. J Pathol. 251:100–112. 2020. View Article : Google Scholar : PubMed/NCBI
12	Marchione DM, Ilieva I, Devins K, Sharpe D, Pappin DJ, Garcia BA, Wilson JP and Wojcik JB: HYPERsol: High-quality data from archival FFPE tissue for clinical proteomics. J Proteome Res. 19:973–983. 2020. View Article : Google Scholar : PubMed/NCBI
13	Lang L, Loveless R and Teng Y: Emerging links between control of mitochondrial protein ATAD3A and cancer. Int J Mol Sci. 21:79172020. View Article : Google Scholar : PubMed/NCBI
14	Slizen MV and Galzitskaya OV: Comparative analysis of proteomes of a number of nosocomial pathogens by KEGG modules and KEGG pathways. Int J Mol Sci. 21:78392020. View Article : Google Scholar : PubMed/NCBI
15	Camidge DR, Doebele RC and Kerr KM: Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 16:341–355. 2019. View Article : Google Scholar : PubMed/NCBI
16	Han Z, Feng Y, Gu B, Li Y and Chen H: The post-translational modification, SUMOylation, and cancer (Review). Int J Oncol. 52:1081–1094. 2018.PubMed/NCBI
17	Lu Z and Hunter T: Metabolic kinases moonlighting as protein kinases. Trends Biochem Sci. 43:301–310. 2018. View Article : Google Scholar : PubMed/NCBI
18	Barton MK: Structured palliative care program found to be helpful for caregivers of patients with lung cancer. CA Cancer J Clin. 66:5–6. 2016. View Article : Google Scholar : PubMed/NCBI
19	Xu J, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, Qian K, Sun C, Liu Z, Jiang S, et al: Integrative proteomic characterization of human lung adenocarcinoma. Cell. 182:245–261.e17. 2020. View Article : Google Scholar : PubMed/NCBI
20	Keskin O, Tuncbag N and Gursoy A: Predicting protein-protein interactions from the molecular to the proteome level. Chem Rev. 116:4884–4909. 2016. View Article : Google Scholar : PubMed/NCBI
21	Newton Y, Sedgewick AJ, Cisneros L, Golovato J, Johnson M, Szeto CW, Rabizadeh S, Sanborn JZ, Benz SC and Vaske C: Large scale, robust, and accurate whole transcriptome profiling from clinical formalin-fixed paraffin-embedded samples. Sci Rep. 10:175972020. View Article : Google Scholar : PubMed/NCBI
22	Zhu Y, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, et al: High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. Mol Oncol. 13:2305–2328. 2019. View Article : Google Scholar : PubMed/NCBI
23	Park C, Na KJ, Choi H, Ock CY, Ha S, Kim M, Park S, Keam B, Kim TM, Paeng JC, et al: Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. Theranostics. 10:10838–10848. 2020. View Article : Google Scholar : PubMed/NCBI
24	Xu F, Zhan X, Zheng X, Xu H, Li Y, Huang X, Lin L and Chen Y: A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma. Genomics. 112:4675–4683. 2020. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Jiang W, Li T, Li M, Li X, Zhang Z, Zhang S, Liu Y, Zhao W, Gu Y, et al: Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma. J Transl Med. 18:252020. View Article : Google Scholar : PubMed/NCBI
26	Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, D'Ambrosio L, Pallocca M, Corleone G, Krasniqi E, Pizzuti L, et al: KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol. 12:1746–1754. 2020. View Article : Google Scholar : PubMed/NCBI
27	Wu C and Hwang MJ: Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy. Cancer Med. 8:5850–5861. 2019. View Article : Google Scholar : PubMed/NCBI
28	Du P and Xu C: Predicting multisite protein subcellular locations: Progress and challenges. Expert Rev Proteomics. 10:227–237. 2013. View Article : Google Scholar : PubMed/NCBI
29	Laursen L, Karlsson E, Gianni S and Jemth P: Functional interplay between protein domains in a supramodular structure involving the postsynaptic density protein PSD-95. J Biol Chem. 295:1992–2000. 2020. View Article : Google Scholar : PubMed/NCBI
30	Dawson N, Sillitoe I, Marsden RL and Orengo CA: The classification of protein domains. Methods Mol Biol. 1525:137–164. 2017. View Article : Google Scholar : PubMed/NCBI
31	Zheng W, Zhou X, Wu Q, Pearce R, Li Y and Zhang Y: FUpred: Detecting protein domains through deep-learning-based contact map prediction. Bioinformatics. 12:3749–3757. 2020. View Article : Google Scholar : PubMed/NCBI
32	Libiad M, Motl N, Akey DL, Sakamoto N, Fearon ER, Smith JL and Banerjee R: Thiosulfate sulfurtransferase-like domain-containing 1 protein interacts with thioredoxin. J Biol Chem. 293:2675–2686. 2018. View Article : Google Scholar : PubMed/NCBI
33	Lu Y, Mehta-D'souza P, Biswas I, Villoutreix BO, Wang X, Ding Q and Rezaie AR: Ile73Asn mutation in protein C introduces a new N-linked glycosylation site on the first EGF-domain of protein C and causes thrombosis. Haematologica. 105:1712–1722. 2020. View Article : Google Scholar : PubMed/NCBI
34	Wang F, Wang-Gou S, Cao H, Jiang N and Li X: Proteomics identifies EGF-like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor-positive glioma. Cancer Commun (Lond). 40:518–530. 2020. View Article : Google Scholar : PubMed/NCBI
35	Mizutani K, Guo X, Shioya A, Zhang J, Zheng J, Kurose N, Ishibashi H, Motono N, Uramoto H and Yamada S: The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma. Int J Med Sci. 16:1199–1206. 2019. View Article : Google Scholar : PubMed/NCBI
36	Liang S, Ko JC, Yang J and Shih JY: Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 133:103–109. 2019. View Article : Google Scholar : PubMed/NCBI
37	Neugut AI, MacLean SA, Dai W and Jacobson JS: Physician characteristics and decisions regarding cancer screening: A systematic review. Popul Health Manag. 22:48–62. 2019. View Article : Google Scholar : PubMed/NCBI
38	Heldring N, Nyman U, Lönnerberg P, Onnestam S, Herland A, Holmberg J and Hermanson O: NCoR controls glioblastoma tumor cell characteristics. Neuro Oncol. 16:241–249. 2014. View Article : Google Scholar : PubMed/NCBI
39	Wang H, Gao J, Zhang R, Li M, Peng Z and Wang H: Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. Int Immunopharmacol. 83:1064782020. View Article : Google Scholar : PubMed/NCBI
40	Ni K, Wang D, Xu H, Mei F, Wu C, Liu Z and Zhou B: miR-21 promotes non-small cell lung cancer cells growth by regulating fatty acid metabolism. Cancer Cell Int. 19:2192019. View Article : Google Scholar : PubMed/NCBI
41	Barton MK: Use of posttreatment imaging and biomarker testing for survivors of breast cancer. CA Cancer J Clin. 66:175–176. 2016. View Article : Google Scholar : PubMed/NCBI
42	VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS and Costa DB: Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 116:90–95. 2018. View Article : Google Scholar : PubMed/NCBI
43	Wu Y, Jamal M, Xie T, Sun J, Song T, Yin Q, Li J, Pan S, Zeng X, Xie S and Zhang Q: Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer. Cancer Sci. 110:2734–2747. 2019. View Article : Google Scholar : PubMed/NCBI
44	Gu B and Zhu WG: Surf the post-translational modification network of p53 regulation. Int J Biol Sci. 8:672–684. 2012. View Article : Google Scholar : PubMed/NCBI
45	Teng Y, Lang L and Shay C: ATAD3A on the path to cancer. Adv Exp Med Biol. 1134:259–269. 2019. View Article : Google Scholar : PubMed/NCBI